Name Dr. Aditya Shirish Adhav

CURRICULUM VITAE

Address Adhav Hospital, Shivajinagar, Opp. Inox theatre, Nashik 422006

Phone number 0253-2414959

Mobile number +919860376209

Email address [email protected]

Date of birth 15/08/1987

Languages known English, Marathi and Hindi

Educational details:-

Graduation MBBS 2005-2010(NDMVPS Medical College and Hospital, Nashik) Recognised by Medical Council of India

Internship from Feb. 2010 to Feb. 2011(NDMVPS Medical College and Hospital, Nashik) Post Graduation PDVVPF’s Medical College, Ahmednagar (1st June 2011- 31stMay2014) under Maharashtra University of Health Sciences. Recognised by Medical Council of India Topic of Dissertation: - CLINICO-PATHOLOGICAL STUDY OF NON NEOPLASTIC AND NEOPLASTIC LESIONS OF BREAST WITH RADIOLOGICAL CORRELATION.

Senior resident SMBT Hospital Nasik 18thDec 2014 to 28th Jan 2015

Bharati Vidyapeeth Deemed University, Pune 2nd March 2015 to 30th June 2015.

Fellowship Breast surgery at Manavata Curie Cancer Centre, Nashik affiliated with Maharashtra University of Health Sciences from 2nd July 2015 to 31st Aug 2016.

Achievements: -

Academics Title Year Univers Institute Marks Remarks ity M.S MUHS, PDVVPF’s Medical 61% 1st Attempt General Nashik College, Surgery Ahmednagar MBBS 1st MUHS, NDMVPS Medical 1st Attempt 60% Nashik College 2nd MUHS, NDMVPS Medical 1st Attempt 64% Nashik College 3rd part I MUHS NDMVPS Medical 1st Attempt 61% Nashik College 3rd part II MUHS NDMVPS Medical 1st Attempt 62% Nashik College

Paper Presentation

 Male Breast Lesions: A Scenario at our institute

Poster Presentation

 Benign Multicystic Peritoneal Mesothelioma  Aesthetics in Breast Surgery  Rare But There: Male Breast Cancer

Publications in Indexed Journal

 Benign Multicystic Peritoneal Mesothelioma  Amyand’s Hernia A Rare Sliding Hernia  Rare But There: Male Breast Cancer.

 Intracystic Papillary Carcinoma Of Breast: A Case Report.

 Anterior Mediastinal Mass: A Case Report Of Thymoma With Myasthenia Gravis.  Kikuchi Fujimoto Disease: A Rare Benign Disease.

Conferences Attended

1. Attended MASICON 2012 in Pune. 2. Poster presentation “Benign Multicystic Peritoneal Mesothelioma” in Nashik MASICON 2013. 3. Attended ASICON at Ahmedabad in 2013. 4. Paper presentation “Male Breast Lesions: A Scenario at our institute” at MASICON 2014.

5. Organised and attended Live Operative workshop and Multidisciplinary CME on Breast Surgery at Curie Manavata Cancer Centre Nashik October 2015.

6. Attended Current trends in Oncology Breast Chapter - 2016 at Ruby Hall Clinic, Pune. PRINCIPAL INVESTIGATOR IN

1) A Randomised double-blind study in two parts Part A – Comparing two humanized monoclonal antibodies that target VEGF in combination with mFOLFOX6 in patients with non-resectable metastatic colorectal cancer (mCRC) and Part B – Comparing two humanized monoclonal antibodies that target VEGF in combination with pemetrexed and carboplatin in recurrent or advanced nonsquemous non-small cell lung cancer (NSCLC).

2) A Randomized, Double-Blind, Multi- Centre, Parallel Group Study Comparing Two Humanized Monoclonal Antibodies that Target HER2 Receptors in Combination with Paclitaxel Administered as First-Line Treatment in Patients with HER2 -Positive Metastatic Breast Cancer. 3) A Randomized, Open Label, Two Period, Single Dose, Crossover, Bioavailability Study Of Paclitaxel Injection Concentrate For Nano- Dispersion (PICN) And Abraxane® In Subjects With Locally Recurrent Or Metastatic Breast Cancer

SUB INVESTIGATOR IN 1) Prospective, multi-centric, randomized open-label, twoarm, parallel group, active-control, comparative clinical study to evaluate efficacy, safety and pharmacokinetics of R-TPR- 033 / Erbitux ® in patients with recurrent locoregional or metastatic squamous cell carcinoma of the head and neck.

2) A Prospective, Randomized, Multi- Centre Study to Compare the Safety, Tolerability, and Efficacy Bevacizumab (Zydus Cadila) With Bevacizumab (Avastin ®) in Non-Small Cell Lung Cancer (NSCLC).

3) A Randomized,Double-blind,Placebo- controlled study to Evaluate the Long- term Safety and Efficacy of Darbepoetin Alpha Administered at 500mg once- Every-3- weeks in Anemic Subjects with Advanced Stage Non-small cell Lung Cancer Receiving Multi- cycle Chemotherapy.

4) A Prospective, Comparative, Open Label, Randomized, Multicentric, Phase III study to compare the safety and efficacy of Bevacizumab of Inta Pharmaceuticals Limited against Avastin™ in Patients with Unresectable or Metastatic Non-Squamous Non - Small Cell Lung Cancer.